Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16572379 | 0.71 | HSD11B1 (0.38) | GAAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL15466074 | 0.70 | ALDH1A1 (0.36) | GAAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL11616927 | 0.70 | ALDH1A1 (0.42) | GAAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL2318962 | 0.70 | ALDH1A1 (0.42) | GAAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL11618552 | 0.70 | ALDH1A1 (0.36) | GAAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL7861816 | 0.69 | — | — | |
| SCHEMBL4148665 | 0.67 | ALDH1A1 (0.36) | GAAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL1765776 | 0.67 | PTGES (0.35) | GAAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL15418543 | 0.67 | HSD17B10 (0.35) | GAAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL10932007 | 0.65 | ALDH1A1 (0.33) | GAAKDM4EMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | MKI67, CCNB1, RB1 | GAA 4328/4885KDM4E 1597/4885MEN1 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.